Search

Ian J Popoff

from Encinitas, CA
Age ~52
Get Report
Also known as:
Pi G, Pi L
Phone and address:
630 Brae Mar Ct, Encinitas, CA 92024
(760) 470-6220
Related to:
Madelyn Popoff, 41Madelyn PopoffChristine M Popoff, 41Tawnya PopoffStephanie A Bambrook, 63Michael Bambrook, 72Jerry A Popoff, 83
Connected to:
Angela M Popoff, 53Anita Y Popoff, 42Daniel Popoff, 56Gary D Popoff, 77Katherine Popoff, 38Marc A Popoff, 67Marcus W Popoff, 52Serge P Popoff, 92Rita T Popojas, 74Steven M Popok, 68

Ian Popoff Phones & Addresses

  • 630 Brae Mar Ct, Encinitas, CA 92024 (760) 470-6220
  • 271 Hillcrest Dr, Encinitas, CA 92024
  • 904 Hygeia Ave, Encinitas, CA 92024
  • 214 Coneflower St, Encinitas, CA 92024
  • Idyllwild, CA
  • Oceanside, CA
  • Cardiff by the Sea, CA
  • San Diego, CA
  • Carlsbad, CA

Work

Company: Halozyme therapeutics, inc. Mar 2019 Position: Executive director, project management

Education

Degree: Master of Business Administration, Masters School / High School: University of California, Irvine - the Paul Merage School of Business 2003 to 2005

Skills

Pharmaceutical Industry • Drug Development • Biotechnology • Oncology • Drug Discovery • Clinical Development • Regulatory Submissions • Biopharmaceuticals • Life Sciences • Cross Functional Team Leadership • Process Improvement • Clinical Trials • Cro • Fda • Pharmacology • Lifesciences • Resource Management • Project Management Office • Strategic Planning • Corporate Governance • Portfolio Management • Problem Solving • Critical Thinking • Risk Assessment • Project Portfolio Management • Program Management • Business Strategy • Operational Excellence • Entrepreneurship • Budget Management • Business Process Improvement • Change Management • Business Planning • Business Development • Public Speaking • Presentation Skills • Negotiation • Written Communication • Interpersonal Communication • Biologics • Translational Medicine • Life Science Industry • Business Operations • Operational Strategy • Pre Clinical Studies • Small Molecules • Decision Analysis • Workforce Development • Data Analytics • Infrastructure Development • Quantitative Analytics • Financial Modeling

Industries

Pharmaceuticals

Resumes

Resumes

Ian Popoff Photo 1

Executive Director, Head, Project Management

View page
Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Halozyme Therapeutics, Inc.
Executive Director, Project Management
Pfizer Apr 2015 - Nov 2018
Senior Director, Strategic Portfolio Intelligence and Prioritization
Pfizer Feb 2006 - Apr 2015
Director, Portfolio Management
Pfizer Feb 2006 - Apr 2015
Drug Development Professional - Additional Capabilities
Pfizer Apr 2004 - Feb 2006
Project Manager
Education:
University of California, Irvine - the Paul Merage School of Business 2003 - 2005
Master of Business Administration, Masters University of Calgary
Master of Science, Masters, Immunology
Skills:
Pharmaceutical Industry
Drug Development
Biotechnology
Oncology
Drug Discovery
Clinical Development
Regulatory Submissions
Biopharmaceuticals
Life Sciences
Cross Functional Team Leadership
Process Improvement
Clinical Trials
Cro
Fda
Pharmacology
Lifesciences
Resource Management
Project Management Office
Strategic Planning
Corporate Governance
Portfolio Management
Problem Solving
Critical Thinking
Risk Assessment
Project Portfolio Management
Program Management
Business Strategy
Operational Excellence
Entrepreneurship
Budget Management
Business Process Improvement
Change Management
Business Planning
Business Development
Public Speaking
Presentation Skills
Negotiation
Written Communication
Interpersonal Communication
Biologics
Translational Medicine
Life Science Industry
Business Operations
Operational Strategy
Pre Clinical Studies
Small Molecules
Decision Analysis
Workforce Development
Data Analytics
Infrastructure Development
Quantitative Analytics
Financial Modeling

Publications

Us Patents

Antisense Modulation Of Damage-Specific Dna Binding Protein 2, P48 Expression

View page
US Patent:
6379960, Apr 30, 2002
Filed:
Dec 6, 2000
Appl. No.:
09/732199
Inventors:
Ian Popoff - Encinitas CA
Jacqueline Wyatt - Encinitas CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C12Q 168
US Classification:
435375, 435 6, 435 911, 435366, 536 231, 536 2431, 536 2433, 536 245
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 2, p48. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 2, p48. Methods of using these compounds for modulation of Damage-specific DNA binding protein 2, p48 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 2, p48 are provided.

Antisense Modulation Of Parp Expression

View page
US Patent:
6451602, Sep 17, 2002
Filed:
Mar 2, 2000
Appl. No.:
09/517467
Inventors:
Ian Popoff - Encinitas CA
Lex M. Cowsert - Carlsbad CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C12Q 168
US Classification:
435375, 435 6, 435 911, 435325, 435366, 536 231, 536 2431, 536 2433, 536 245
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of human PARP. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding human PARP. Methods of using these compounds for modulation of human PARP expression and for treatment of diseases associated with expression of human PARP are provided.

Antisense Modulation Of Ptpn2 Expression

View page
US Patent:
6485974, Nov 26, 2002
Filed:
May 18, 2001
Appl. No.:
09/861159
Inventors:
Ian Popoff - Encinitas CA
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C12N 500
US Classification:
435375, 435 6, 435325, 536 231, 536 243, 536 2431, 536 2433, 536 245
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of PTPN2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN2. Methods of using these compounds for modulation of PTPN2 expression and for treatment of diseases associated with expression of PTPN2 are provided.

Antisense Modulation Of Damage-Specific Dna Binding Protein 1, P127 Expression

View page
US Patent:
6855700, Feb 15, 2005
Filed:
Dec 6, 2000
Appl. No.:
09/731457
Inventors:
Ian Popoff - Encinitas CA, US
Jacqueline Wyatt - Encinitas CA, US
Assignee:
ISIS Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
A61K041/00
C07H021/04
US Classification:
514 44, 435 6, 435325, 435375, 536 231, 536 245
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Damage-specific DNA binding protein 1, p127. Methods of using these compounds for modulation of Damage-specific DNA binding protein 1, p127 expression and for treatment of diseases associated with expression of Damage-specific DNA binding protein 1, p127 are provided.

Antisense Modulation Of P38 Mitogen Activated Protein Kinase Expression

View page
US Patent:
7981868, Jul 19, 2011
Filed:
Aug 12, 2004
Appl. No.:
10/568488
Inventors:
Brett P. Monia - Carlsbad CA, US
Kenneth W. Dobie - Del Mar CA, US
Susan M. Freier - San Diego CA, US
Ian Popoff - Encinitas CA, US
James G. Karras - San Marcos CA, US
Assignee:
Isis Pharmaceuticals, Inc. - Carlsbad CA
International Classification:
C07H 21/00
C07H 21/02
C12N 15/11
A61K 48/00
US Classification:
514 44, 536 231, 536 243, 536 2433, 536 245
Abstract:
Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for decreasing airway hyperresponsiveness or airway inflammation in an animal are also provided.

Passenger Safety Handlebar

View page
US Patent:
20030006082, Jan 9, 2003
Filed:
Jul 5, 2001
Appl. No.:
09/898662
Inventors:
Ian Popoff - Encinitas CA, US
International Classification:
B60R021/00
US Classification:
180/271000, 280/748000
Abstract:
The inventor, Ian Popoff, of Encinitas, Calif., wishes to disclose the novel utility of the Passenger Safety Handlebar. The Passenger Safety Handlebar is a fixed-mounted device to be used with in-line-seating arrangement vehicles, such as motorcycles, snowmobiles, personal watercraft, all-terrain vehicles, and the like, to improve passenger safety and stability while using such vehicles. What is novel with respect to the Passenger Safety Handlebar is primarily the secured-mounting properties of the device to the vehicle (as opposed to the driver of such vehicle), which are not observed in the prior art. Second, the innate nature of the Passenger Safety Handlebar predisposes it against action or movement of either the passenger or driver to each other. Further, the actual location of the Passenger Safety Handlebar is novel with respect to prior art, in that it is forward of the driver of the vehicle, rather than lateral or behind. The improvements over prior inventions are that the Passenger Safety Handlebar does not direct any of the passenger's movements to the driver of the vehicle, and further allow the passenger to transfer all of their inertia to the vehicle through the device, which is exceptionally important during braking and acceleration. The use of such a device improves the passenger's upright stability, and benefits the driver directly by removing the necessity for supporting the passenger during braking and acceleration, and by encouraging a proper vertical positioning of the passenger during turning.

Antisense Modulation Of E2F Transcription Factor 2 Expression

View page
US Patent:
20040048818, Mar 11, 2004
Filed:
Aug 25, 2003
Appl. No.:
10/380125
Inventors:
Ian Popoff - Encinitas CA, US
Jacqueline Wyatt - Encinitas CA, US
International Classification:
A61K048/00
C07H021/04
US Classification:
514/044000, 536/023200
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of E2F transcription factor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding E2F transcription factor 2. Methods of using these compounds for modulation of E2F transcription factor 2 expression and for treatment of diseases associated with expression of E2F transcription factor 2 provided.

Compositions And Their Uses Directed To Cell Growth And Maintenance Proteins

View page
US Patent:
20050186594, Aug 25, 2005
Filed:
Dec 17, 2004
Appl. No.:
11/015161
Inventors:
C. Bennett - Carlsbad CA, US
Susan Freier - San Diego CA, US
Nicholas Dean - Olivenhain CA, US
Ian Popoff - Encinitas CA, US
Brett Monia - Encinitas CA, US
Donna Ward - Carlsbad CA, US
Ming-Yi Chiang - San Diego CA, US
Ravi Jain - Carlsbad CA, US
Kenneth Dobie - Del Mar CA, US
International Classification:
A61K048/00
C12Q001/68
C07H021/04
US Classification:
435006000, 514044000, 536023100
Abstract:
Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor kinase 6. Methods of using these compounds for modulation of G protein-coupled receptor kinase 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor kinase 6 are provided.
Control profile
Ian J Popoff from Encinitas, CA, age ~52 Get Report